SurvExpress data revealed that levels of PAK2 are significantly elevated in high‐risk groups of patients suffering from Burkitt lymphoma (BL), multiple myeloma (MM), diffuse large B‐cell lymphoma (DLBCL), and mantle cell lymphoma (MCL) (Figs 1A and S1A). The gene discussed is PAK2; the disease is plasma cell myeloma.